Selpercatinib
- Generic Name
- Selpercatinib
- Brand Names
- Retevmo, Retsevmo
- Drug Type
- Small Molecule
- Chemical Formula
- C29H31N7O3
- CAS Number
- 2152628-33-4
- Unique Ingredient Identifier
- CEGM9YBNGD
- Background
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes. Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including cabozantinib, ponatinib, sorafenib, sunitinib, and vandetanib, have shown efficacy in RET-dri...
- Indication
Selpercatinib is approved to treat:
Selpercatinib is currently approved for these indications under an accelerated approval scheme and continued approval may be contingent on future confirmatory trials.
- Associated Conditions
- Locally Advanced Solid Neoplasm, Metastatic Solid Neoplasm, Advanced RET-fusion thyroid cancer, Advanced RET-mutant medullary thyroid cancer, Metastatic RET-fusion Non Small Cell Lung Cancer, Metastatic RET-fusion thyroid cancer, Metastatic RET-mutant medullary thyroid cancer
- Associated Therapies
- -
The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy
- Conditions
- Interventions
- Drug: Oncology DrugsDrug: ErlotinibDrug: TrastuzumabDrug: Trastuzumab emtansineDrug: PertuzumabDrug: LapatinibDrug: EverolimusDrug: VemurafenibDrug: CobimetinibDrug: AlectinibDrug: BrigatinibDrug: PalbociclibDrug: PonatinibDrug: VismogedibDrug: ItacitinibDrug: IpatasertibDrug: EntrectinibDrug: AtezolizumabDrug: NivolumabDrug: IpilimumabDrug: PemigatinibDrug: PralsetinibDrug: SelpercatinibDrug: TalazoparibDrug: TepotinibDrug: Alpelisib
- First Posted Date
- 2020-10-19
- Last Posted Date
- 2023-10-03
- Lead Sponsor
- Fondazione per la Medicina Personalizzata
- Target Recruit Count
- 400
- Registration Number
- NCT04591431
- Locations
- 🇮🇹
I.R.S.T. Srl Irccs, Meldola, Italy
🇮🇹Ospedale Classificato Sacro Cuore - Don Calabria, Negrar, Italy
🇮🇹I.R.C.C.S. Istituto Oncologico Veneto, Padova, Italy
Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial
- Conditions
- Refractory Histiocytic and Dendritic Cell NeoplasmRecurrent EpendymomaRecurrent Histiocytic and Dendritic Cell NeoplasmRecurrent Ewing SarcomaRecurrent HepatoblastomaRecurrent Malignant GliomaRecurrent Malignant Solid NeoplasmRecurrent RhabdomyosarcomaRecurrent WHO Grade 2 GliomaRefractory Malignant Germ Cell Tumor
- Interventions
- First Posted Date
- 2020-03-25
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 1
- Registration Number
- NCT04320888
- Locations
- 🇺🇸
Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta, Georgia, United States
🇺🇸Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸Providence Alaska Medical Center, Anchorage, Alaska, United States
A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation
- Conditions
- Interventions
- First Posted Date
- 2020-02-21
- Last Posted Date
- 2024-03-01
- Lead Sponsor
- Loxo Oncology, Inc.
- Target Recruit Count
- 77
- Registration Number
- NCT04280081
- Locations
- 🇨🇳
The First Affiated Hospital Of Guangzhou Medical University, Guangzhou, Guangdong, China
🇨🇳Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
🇨🇳Beijing Cancer Hospital, Beijing, Beijing, China
Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial)
- Conditions
- Interventions
- First Posted Date
- 2020-02-13
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 124
- Registration Number
- NCT04268550
- Locations
- 🇺🇸
Columbus Oncology and Hematology Associates Inc, Columbus, Ohio, United States
🇺🇸The Mark H Zangmeister Center, Columbus, Ohio, United States
🇺🇸Doctors Hospital, Columbus, Ohio, United States
A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-12-26
- Last Posted Date
- 2024-06-13
- Lead Sponsor
- Loxo Oncology, Inc.
- Target Recruit Count
- 291
- Registration Number
- NCT04211337
- Locations
- 🇺🇸
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, California, United States
🇺🇸University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-12-11
- Last Posted Date
- 2024-06-20
- Lead Sponsor
- Loxo Oncology, Inc.
- Target Recruit Count
- 261
- Registration Number
- NCT04194944
- Locations
- 🇨🇳
The First Affiated Hospital Of Guangzhou Medical Collage, Guangzhou, Guangzhou, China
🇦🇷Alexander Fleming, Ciudad de Buenos Aires, Argentina
🇨🇳Buddhist Dalin Tzu Chi General Hospital, Dalin Town, Chiayi, Taiwan
Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)
- Conditions
- Interventions
- First Posted Date
- 2019-05-10
- Last Posted Date
- 2024-07-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 248
- Registration Number
- NCT03944772
- Locations
- 🇸🇪
Research Site, Stockholm, Sweden
Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation
- First Posted Date
- 2019-04-08
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Loxo Oncology, Inc.
- Registration Number
- NCT03906331
- Locations
- 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸Mayo Clinic of Scottsdale, Scottsdale, Arizona, United States
🇺🇸City of Hope National Medical Center, Duarte, California, United States
A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors
- Conditions
- Interventions
- First Posted Date
- 2019-04-02
- Last Posted Date
- 2024-03-07
- Lead Sponsor
- Loxo Oncology, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT03899792
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)
- Conditions
- Interventions
- First Posted Date
- 2017-05-17
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Loxo Oncology, Inc.
- Target Recruit Count
- 856
- Registration Number
- NCT03157128
- Locations
- 🇯🇵
Okayama University Hospital, Okayama, Japan
🇺🇸Mayo Clinic of Scottsdale, Scottsdale, Arizona, United States
🇺🇸City of Hope National Medical Center, Duarte, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.